{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:03:38Z","timestamp":1789844618646,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40264-024-01425-5","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T22:56:11Z","timestamp":1713653771000},"page":"699-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Composite Plot for Visualizing Aminotransferase and Bilirubin Changes in Clinical Trials of Subjects with Abnormal Baseline Values"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-0755","authenticated-orcid":false,"given":"Bereket","family":"Tesfaldet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Pucino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilliam","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Navarro Almario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"1425_CR1","unstructured":"US FDA. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment guidance for industry. 2017. [Online]. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chronic-hepatitis-c-virus-infection-developing-direct-acting-antiviral-drugs-treatment-guidance. Accessed 15 June 2023."},{"key":"1425_CR2","unstructured":"US FDA. Chronic hepatitis B virus infection: developing drugs for treatment guidance for industry. 2022. [Online]. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chronic-hepatitis-b-virus-infection-developing-drugs-treatment. Accessed 15 June 2023."},{"key":"1425_CR3","unstructured":"US FDA. Drug-induced liver injury: premarketing clinical evaluation. 2009. [Online]. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation. Accessed 15 June 2023."},{"issue":"4","key":"1425_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","volume":"15","author":"R Temple","year":"2006","unstructured":"Temple R. Hy\u2019s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241\u20133.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1425_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40264-020-01014-2","volume":"44","author":"WR Treem","year":"2021","unstructured":"Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and nonalcoholic. Drug Saf. 2021;44(2):133\u201365.","journal-title":"Drug Saf"},{"issue":"Suppl","key":"1425_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40264-014-0186-3","volume":"37","author":"GA Kullak-Ublick","year":"2014","unstructured":"Kullak-Ublick GA, Merz M, Griffel L, Kaplowitz N, Watkins PB. Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf. 2014;37(Suppl):57\u201362.","journal-title":"Drug Saf"},{"key":"1425_CR7","doi-asserted-by":"crossref","unstructured":"Senior J, Guo T. Hy\u2019s law and eDISH for clinical studies. In: Chen M, Will Y, editors. Drug-induced liver toxicity. New York, NY: Springer; 2018. p. 411\u2013429.","DOI":"10.1007\/978-1-4939-7677-5_20"},{"key":"1425_CR8","unstructured":"Guo T, Senior J, Gelperin K. How a SAS\/IntrNet tool was created at the FDA for the detection of potential druginduced liver injury using data with CDISC standard. In: Proceedings of the Western Users of SAS Software Annual Conference, San Diego, California, 2009."},{"issue":"Suppl 1","key":"1425_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40264-014-0182-7","volume":"37","author":"J Senior","year":"2014","unstructured":"Senior J. Evolution of the food and drug administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37(Suppl 1):9\u201317.","journal-title":"Drug Saf"},{"issue":"3","key":"1425_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","volume":"34","author":"PB Watkins","year":"2011","unstructured":"Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, Maddrey W. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug-Saf. 2011;34(3):243\u201352.","journal-title":"Drug-Saf"},{"key":"1425_CR11","unstructured":"US FDA. https:\/\/www.accessdata.fda.gov. 01 03 2022. [Online]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020903s057,021546s013lbl.pdf. Accessed 22 Jan 2024."},{"issue":"Suppl 1","key":"1425_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-014-0184-5","volume":"37","author":"M Merz","year":"2014","unstructured":"Merz M, Lee KR, Kullak-Ublick GA, Brueckner A, Watkins PB. Methodology to assess clinical liver safety data. Drug Saf. 2014;37(Suppl 1):33\u201345.","journal-title":"Drug Saf"},{"key":"1425_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/BF03261982","volume":"35","author":"X Lin","year":"2012","unstructured":"Lin X, Parks D, Painter J, Hunt C, Stirnadel-Farrant H, Cheng J, Menius A, Lee K. Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations. Drug Saf. 2012;35:865\u201375.","journal-title":"Drug Saf"},{"key":"1425_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/pds.3405","volume":"22","author":"D Parks","year":"2013","unstructured":"Parks D, Lin X, Painter J, Cheng J, Hunt C, Spraggs C, Nelson J, Curtis L, Menius A, Lee K. A proposed modification to Hy\u2019s law and Edish criteria in oncology clinical trials using aggregated historical data. Pharmacoepidemiol Drug Saf. 2013;22:571\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1425_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.17849\/insm-49-3-172-182.1","volume":"49","author":"S Rigatti","year":"2022","unstructured":"Rigatti S, Stout R. Association of liver function tests with mortality in an insurance applicant population. J Insur Med. 2022;49:172\u201382.","journal-title":"J Insur Med"},{"key":"1425_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1024\/0040-5930\/a001206","volume":"77","author":"C Keerl","year":"2020","unstructured":"Keerl C, Bernsmeier C. Erh\u00f6hte Leberwerte \u2013 Zufallsbefund in der Hausarztpraxis [Elevated liver function tests\u2014as incidental finding in general practice]. Therapeutische Umschau Revue therapeutique. 2020;77:371\u20138.","journal-title":"Therapeutische Umschau. Revue therapeutique"},{"key":"1425_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1572-0241.2005.00341.x","volume":"101","author":"G Ioannou","year":"2006","unstructured":"Ioannou G, Boyko E, Lee S. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999\u20132002. Am J Gastroenterol. 2006;101:76\u201382.","journal-title":"Am J Gastroenterol"},{"key":"1425_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00228-009-0684-x","volume":"65","author":"Z Cai","year":"2009","unstructured":"Cai Z, Christianson A, St\u00e5hle L, Keisu M. Reexamining transaminase elevation in phase I clinical trials: the importance of baseline and change from baseline. Eur J Clin Pharmacol. 2009;65:1025\u201335.","journal-title":"Eur J Clin Pharmacol"},{"key":"1425_CR19","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s10620-019-05591-w","volume":"64","author":"J Ahmad","year":"2019","unstructured":"Ahmad J, Reddy R, Tillmann H, Hayashi P, Chalasani N, Fontana R, Navarro V, Stolz A, Barnhart H, Cloherty G, Hoofnagle J. Importance of hepatitis C virus RNA testing in patients with suspected drug-induced liver injury. Digest Dis Sci. 2019;64:2645\u201352.","journal-title":"Digest Dis Sci"},{"issue":"Suppl 1","key":"1425_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-014-0183-6","volume":"37","author":"M Avigan","year":"2014","unstructured":"Avigan M, Bj\u00f6rnsson E, Pasanen M, Cooper C, Andrade R, Watkins P, Lewis J, Merz M. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf. 2014;37(Suppl 1):19\u201331.","journal-title":"Drug Saf"},{"issue":"2","key":"1425_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/cts.12629","volume":"12","author":"PB Watkins","year":"2019","unstructured":"Watkins PB. The DILI-sim initiative: insights into hepatotoxicity mechanisms and biomarker interpretation. Clin Transl Sci. 2019;12(2):122\u20139.","journal-title":"Clin Transl Sci"},{"key":"1425_CR22","unstructured":"US FDA. Providing regulatory submissions in electronic format\u2014standardized study data. 2014. [Online]. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/providing-regulatory-submissions-electronic-format-standardized-study-data. Accessed 15 Jun 2023."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01425-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01425-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01425-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T03:22:56Z","timestamp":1718594576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01425-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01425-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"17 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"All code for the Composite eDISH plot (DOI 10.5281\/zenodo.10892050) are available at\n                      \n                      . The software is government data being released in the USA as public domain, and elsewhere, an MIT license applies to all code.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The views expressed in this article are those of the authors and do not necessarily represent the policy of FDA.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Method conception and data collection: Bereket Tesfaldet, Tejas Patel, Eileen Navarro Almario. Analysis and interpretation of results: Bereket Tesfaldet, Tejas Patel, Eileen Navarro Almario, Minjun Chen, Frank Pucino, Paul Hayashi. Draft manuscript preparation: Bereket Tesfaldet, Eileen Navarro Almario, Paul Hayashi, Minjun Chen, Frank Pucino, Tejas Patel, Lilliam Rosario. All authors reviewed the results and approved the final version of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}